vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与SUPERIOR GROUP OF COMPANIES, INC.（SGC）财务数据对比。点击上方公司名可切换其他公司
SUPERIOR GROUP OF COMPANIES, INC.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.9倍（$146.6M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 0.8%），SUPERIOR GROUP OF COMPANIES, INC.自由现金流更多（$17.9M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 2.7%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
舒必利尔集团（Superior Coach）曾是美国汽车工业的车身制造商，其前身加尔福德卡车公司成立于1909年。该企业最为人熟知的业务是打造灵车等专业车辆车身以及校车车身。受1970年代末两大业务板块的严重衰退影响，公司于1980年被母公司清算，1925年至1980年间，企业总部设于俄亥俄州利马市。
PBYI vs SGC — 直观对比
营收规模更大
SGC
是对方的1.9倍
$75.5M
营收增速更快
PBYI
高出26.9%
0.8%
自由现金流更多
SGC
多$3.5M
$14.4M
两年增速更快
PBYI
近两年复合增速
2.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $146.6M |
| 净利润 | — | $3.5M |
| 毛利率 | 69.3% | 36.9% |
| 营业利润率 | 22.7% | 2.8% |
| 净利率 | — | 2.4% |
| 营收同比 | 27.7% | 0.8% |
| 净利润同比 | — | 65.8% |
| 每股收益（稀释后） | $0.26 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYISGC
| Q4 25 | $75.5M | $146.6M | ||
| Q3 25 | $54.5M | $138.5M | ||
| Q2 25 | $52.4M | $144.0M | ||
| Q1 25 | $46.0M | $137.1M | ||
| Q4 24 | $59.1M | $145.4M | ||
| Q3 24 | $80.5M | $149.7M | ||
| Q2 24 | $47.1M | $131.7M | ||
| Q1 24 | $43.8M | $138.8M |
净利润PBYISGC
| Q4 25 | — | $3.5M | ||
| Q3 25 | $8.8M | $2.7M | ||
| Q2 25 | $5.9M | $1.6M | ||
| Q1 25 | $3.0M | $-758.0K | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $20.3M | $5.4M | ||
| Q2 24 | $-4.5M | $600.0K | ||
| Q1 24 | $-4.8M | $3.9M |
毛利率PBYISGC
| Q4 25 | 69.3% | 36.9% | ||
| Q3 25 | 77.7% | 38.3% | ||
| Q2 25 | 76.5% | 38.4% | ||
| Q1 25 | 77.1% | 36.8% | ||
| Q4 24 | 76.4% | 37.1% | ||
| Q3 24 | 63.9% | 40.4% | ||
| Q2 24 | 77.4% | 38.5% | ||
| Q1 24 | 75.5% | 39.8% |
营业利润率PBYISGC
| Q4 25 | 22.7% | 2.8% | ||
| Q3 25 | 17.6% | 2.3% | ||
| Q2 25 | 12.7% | 1.3% | ||
| Q1 25 | 8.7% | -0.7% | ||
| Q4 24 | 22.6% | 1.7% | ||
| Q3 24 | 27.4% | 4.4% | ||
| Q2 24 | -4.6% | 0.5% | ||
| Q1 24 | -5.3% | 3.3% |
净利率PBYISGC
| Q4 25 | — | 2.4% | ||
| Q3 25 | 16.2% | 2.0% | ||
| Q2 25 | 11.2% | 1.1% | ||
| Q1 25 | 6.5% | -0.6% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | 25.2% | 3.6% | ||
| Q2 24 | -9.6% | 0.5% | ||
| Q1 24 | -11.0% | 2.8% |
每股收益（稀释后）PBYISGC
| Q4 25 | $0.26 | $0.23 | ||
| Q3 25 | $0.17 | $0.18 | ||
| Q2 25 | $0.12 | $0.10 | ||
| Q1 25 | $0.06 | $-0.05 | ||
| Q4 24 | $0.40 | $0.12 | ||
| Q3 24 | $0.41 | $0.33 | ||
| Q2 24 | $-0.09 | $0.04 | ||
| Q1 24 | $-0.10 | $0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $23.7M |
| 总债务越低越好 | $22.7M | $94.1M |
| 股东权益账面价值 | $130.3M | $192.8M |
| 总资产 | $216.3M | $421.8M |
| 负债/权益比越低杠杆越低 | 0.17× | 0.49× |
8季度趋势，按日历期对齐
现金及短期投资PBYISGC
| Q4 25 | $97.5M | $23.7M | ||
| Q3 25 | $94.4M | $16.7M | ||
| Q2 25 | $96.0M | $21.0M | ||
| Q1 25 | $93.2M | $19.8M | ||
| Q4 24 | $101.0M | $18.8M | ||
| Q3 24 | $96.7M | $18.4M | ||
| Q2 24 | $96.8M | $13.4M | ||
| Q1 24 | $107.2M | $22.0M |
总债务PBYISGC
| Q4 25 | $22.7M | $94.1M | ||
| Q3 25 | $34.0M | $100.0M | ||
| Q2 25 | $45.3M | $99.3M | ||
| Q1 25 | $56.7M | $95.7M | ||
| Q4 24 | $68.0M | $86.0M | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — | ||
| Q1 24 | $102.0M | — |
股东权益PBYISGC
| Q4 25 | $130.3M | $192.8M | ||
| Q3 25 | $115.3M | $193.8M | ||
| Q2 25 | $104.7M | $192.1M | ||
| Q1 25 | $97.1M | $194.4M | ||
| Q4 24 | $92.1M | $198.9M | ||
| Q3 24 | $71.1M | $199.5M | ||
| Q2 24 | $48.5M | $200.9M | ||
| Q1 24 | $51.0M | $200.8M |
总资产PBYISGC
| Q4 25 | $216.3M | $421.8M | ||
| Q3 25 | $202.9M | $415.3M | ||
| Q2 25 | $194.9M | $423.3M | ||
| Q1 25 | $196.2M | $411.0M | ||
| Q4 24 | $213.3M | $415.1M | ||
| Q3 24 | $220.7M | $407.4M | ||
| Q2 24 | $205.0M | $400.3M | ||
| Q1 24 | $214.1M | $408.5M |
负债/权益比PBYISGC
| Q4 25 | 0.17× | 0.49× | ||
| Q3 25 | 0.30× | 0.52× | ||
| Q2 25 | 0.43× | 0.52× | ||
| Q1 25 | 0.58× | 0.49× | ||
| Q4 24 | 0.74× | 0.43× | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $18.4M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $17.9M |
| 自由现金流率自由现金流/营收 | 19.1% | 12.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 5.32× |
| 过去12个月自由现金流最近4个季度 | $41.7M | $15.8M |
8季度趋势，按日历期对齐
经营现金流PBYISGC
| Q4 25 | $14.4M | $18.4M | ||
| Q3 25 | $9.7M | $-1.7M | ||
| Q2 25 | $14.1M | $4.9M | ||
| Q1 25 | $3.6M | $-2.0M | ||
| Q4 24 | $15.6M | $8.9M | ||
| Q3 24 | $11.0M | $8.2M | ||
| Q2 24 | $1.0M | $6.9M | ||
| Q1 24 | $11.2M | $9.4M |
自由现金流PBYISGC
| Q4 25 | $14.4M | $17.9M | ||
| Q3 25 | $9.7M | $-2.4M | ||
| Q2 25 | $14.1M | $3.3M | ||
| Q1 25 | $3.6M | $-3.1M | ||
| Q4 24 | $15.6M | $7.4M | ||
| Q3 24 | $11.0M | $7.3M | ||
| Q2 24 | $1.0M | $5.6M | ||
| Q1 24 | — | $8.8M |
自由现金流率PBYISGC
| Q4 25 | 19.1% | 12.2% | ||
| Q3 25 | 17.7% | -1.7% | ||
| Q2 25 | 26.8% | 2.3% | ||
| Q1 25 | 7.7% | -2.3% | ||
| Q4 24 | 26.4% | 5.1% | ||
| Q3 24 | 13.7% | 4.9% | ||
| Q2 24 | 2.1% | 4.2% | ||
| Q1 24 | — | 6.3% |
资本支出强度PBYISGC
| Q4 25 | 0.0% | 0.4% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.1% | 0.8% | ||
| Q4 24 | 0.0% | 1.0% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.0% | 1.0% | ||
| Q1 24 | 0.0% | 0.5% |
现金转化率PBYISGC
| Q4 25 | — | 5.32× | ||
| Q3 25 | 1.10× | -0.61× | ||
| Q2 25 | 2.41× | 3.18× | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | 4.28× | ||
| Q3 24 | 0.54× | 1.52× | ||
| Q2 24 | — | 11.42× | ||
| Q1 24 | — | 2.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
SGC
| Branded Products | $96.9M | 66% |
| Healthcare Apparel | $28.8M | 20% |
| Contact Centers | $21.7M | 15% |
